Description
An allosteric inhibitor of Bcr-Abl (IC50 = 0.121 µM); inhibits the Bcr-Abl mutants Bcr-AblG250E, Bcr-AblE255V, and Bcr-AblM351T (IC50s = 4.52, 0.38, and 0.93 µM, respectively); reduces viral titers in IBV-infected Vero cells at 10 µM; increases survival in a recalcitrant mutant Bcr-AblT315I mouse bone marrow transplantation model at 75 mg/kg
Formal name: N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-benzamide
Synonyms:
Molecular weight: 418.4
CAS: 778277-15-9
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals|Entry/fusion Inhibitors||Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Coronaviruses